Literature DB >> 27836320

Emergency LP in a patient receiving dabigatran after antagonization with idarucizumab.

Tim Bastian Braemswig1, Christoph C Eschenfelder2, Christian H Nolte3.   

Abstract

Idarucizumab is an antibody fragment which is used to reverse the anticoagulant effects of dabigatran. We report on the first successful use of idarucizumab before performing an emergency lumbar puncture in a patient on effective anticoagulation with dabigatran thought to have infective cerebral disease (such as temporal encephalitis).
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27836320     DOI： 10.1016/j.ajem.2016.10.068

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN： 0735-6757            Impact factor:   2.469


  5 in total

1.  Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis.

Authors:  Timothy C Hutcherson; Nicole E Cieri-Hutcherson; Rajvi Bhatt
Journal:  P T       Date:  2017-11

2.  A comparison between vitamin K antagonists and new oral anticoagulants.

Authors:  Oscar M P Jolobe
Journal:  Br J Clin Pharmacol       Date:  2017-07-12       Impact factor: 4.335

3.  Assessment of patients post reversal with idarucizumab.

Authors:  Veronica Raco; Tania Ahuja; David Green
Journal:  J Thromb Thrombolysis       Date:  2018-11       Impact factor: 2.300

4.  Reversal of Dabigatran with Idarucizumab in Acute Subarachnoid Hemorrhage.

Authors:  Jonathan Balakumar; Ruben Santiago; Mark Supino
Journal:  Clin Pract Cases Emerg Med       Date:  2017-10-06

5.  Two Dabigatran Fast Reversals in a 4-month Period - a Case Report.

Authors:  Vítor Fagundes; Mari Mesquita
Journal:  Eur J Case Rep Intern Med       Date:  2019-12-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.